Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Parallel Group, Multicentre, Multinational, Prospective, Open-label Exploratory Study to Evaluate the add-on Effect of Opicapone 50 mg or Levodopa 100 mg as First Strategy for the Treatment of Wearing-off in Patients With Parkinson's Disease.

NCT04990284 is registered in ClinicalTrials.gov with Bial - Portela C S.A. as lead sponsor.

NCT NCT04990284
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04990284 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Parallel Group, Multicentre, Multinational, Prospective, Open-label Exploratory Study to Evaluate the add-on Effect of Opicapone 50 mg or Levodopa 100 mg as First Strategy for the Treatment of Wearing-off in Patients With Parkinson's Disease.
Lead sponsor
Bial - Portela C S.A.
Phase
Phase 4
Overall status
Completed
Start date
November 29, 2021
Completion date
April 4, 2023
Enrollment
106 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

parkinson disease